Please assess the completion status of the following clinical trial:

Trial Title: Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A prior confirmed positive test for COVID19 and lingering symptoms are required for inclusion.~As outlined on the CDC website, lingering symptoms include:~* Tiredness or fatigue~* Difficulty thinking or concentrating (sometimes referred to as brain fog)~* Headache~* Loss of smell or taste~* Dizziness on standing~* Fast-beating or pounding heart (also known as heart palpitations)~* Chest pain~* Difficulty breathing or shortness of breath~* Cough~* Joint or muscle pain~* Depression or anxiety~* Fever~* Symptoms that get worse after physical or mental activities~Exclusion Criteria:~* Viral infections other than COVID-19.~* Clinically significant cardiac disease including uncontrolled congestive heart failure and unstable angina~* Pregnancy~* Females of childbearing potential age not on adequate contraception or lactating~* Subjects receiving systemic corticosteroid treatment within one month of Screening Visit~* Subjects Less than 18 years of age~* Hospitalization within last 6 months due to acute exacerbation of airway disease~* Subjects with a clinically significant abnormal chest x-ray within past 12 months~* Medication changes within one month of study entry~* Subjects who have participated in another investigation drug treatment study within the previous month.~* Subjects with a current history of alcohol or recreational drug abuse.~* Subjects who have taken dietary supplements containing pyruvate within 24 hours prior to the screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Treatment of COVID19 Long Haulers with sodium pyruvate nasal spray (Type: EXPERIMENTAL): This is a single arm, open label study. All subjects will be provided a log for monitoring symptoms associated with Long COVID and asked to record symptom severity using a likert scale for one week. All subjects will then use N115 sodium pyruvate nasal spray 3x daily for an additional week and continue to log their symptoms.

Based on this trial design, predict the completion outcome and termination type (if applicable).